(Reuters) – German biotech group CureVac said on Wednesday its COVID-19 vaccine was shown to be 47% effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.
(Reporting by Ludwig Burger; Editing by Chris Reese)
